论文部分内容阅读
目的评价戊地昔布与吡柔比星联合应用对人肺癌A549细胞的体外抑制作用。方法实验分为四组,分别为对照组、戊地昔布组、吡柔比星组、戊地昔布和吡柔比星联合用药组。用MTT法检测戊地昔布与吡柔比星对人肺癌A549细胞的抑制率,用中效原理分析两者之间的作用。结果戊地昔布和吡柔比星单独或联合用药可时间和浓度依赖性抑制A549细胞的生长(P<0.05或P<0.01)。联合用药组对肿瘤细胞的抑制率比单独用药组明显增高(P<0.05或P<0.01),其IC50均明显降低,合用指数小于1。按用药顺序:戊地昔布和吡柔比星同时用药的抑制率最高,其次是先用吡柔比星再用戊地昔布,抑制率最低者是先用戊地昔布后再用吡柔比星。戊地昔布和吡柔比星合用不同药物浓度依赖关系:除25μmol.L-1吡柔比星和19μmol.L-1戊地昔布合用组及75μmol.L-1戊地昔布与6.3μmol.L-1吡柔比星合用组略呈拮抗作用,其他组合的合用指数均小于1,呈协同作用。结论戊地昔布和吡柔比星联合应用对人肺癌A549细胞有抑制作用且呈协同效应。
Objective To evaluate the inhibitory effect of combination of amoxicillin and pirarubicin on human lung cancer A549 cells in vitro. Methods The experiment was divided into four groups: control group, amoxicillin group, pirarubicin group, amoxicillin and pirarubicin group. The inhibitory rate of amoxicillin and pirarubicin on human lung adenocarcinoma A549 cells was detected by MTT assay, and the effect of the two drugs was analyzed by the principle of neutral effect. Results Both adriamycin and pirarubicin alone or in combination inhibited the growth of A549 cells in a time and concentration-dependent manner (P <0.05 or P <0.01). The inhibitory rate of tumor cells in the combination group was significantly higher than that in the drug alone group (P <0.05 or P <0.01), and the IC50 of the combination group was significantly lower than that in the combination group. The combination index was less than 1. According to the order of administration, the inhibition rate of the combination of amoxicillin and pirarubicin was the highest at the same time, followed by that of pivalodecoxir followed by pirarubicin, and the lowest inhibition rate was that of amoxicillin Romy star. The combination of amoxicillin, epirubicin and pirarubicin in different drug concentration-dependent relationship: except 25μmol.L-1 pirarubicin and 19μmol.L-1 amoxicillin combination group and 75μmol.L-1 amoxicillin and 6.3 μmol.L-1 pirarubicin combination group was slightly antagonistic effect, other combinations combined index were less than 1, a synergistic effect. Conclusion The combination of amoxicillin and pirarubicin has a synergistic effect on human lung cancer A549 cells.